DNM2 and centronuclear myopathy: Notwithstanding the aforementioned sample size and other limitations with our human CNM cases, these findings may suggest that reducing dynamin 2 as a therapeutic strategy may not be appropriate for all forms of human CNM as previously suggested (Demonbreun and McNally, 2014) and may be limited to XLCNM.